cisplatin + fluorouracil or capecitabine or oxaliplatin + capecitabine

This entry refers to a combination chemotherapy regimen involving the following agents: - **Cisplatin**: A platinum-based chemotherapeutic that forms DNA crosslinks and inhibits DNA synthesis and function. - **Fluorouracil** (5-FU): An antimetabolite that inhibits thymidylate synthase and interferes with DNA/RNA synthesis. - **Capecitabine**: An oral prodrug of fluorouracil; it is converted enzymatically in tumor tissue to 5-FU where it acts as an antimetabolite inhibiting DNA synthesis[1][4][8]. - **Oxaliplatin**: A platinum-based chemotherapeutic that causes inter- and intra-strand crosslinks in DNA. These drugs are used alone or in various combinations for the treatment of several solid tumors including colorectal cancer, gastric cancer, esophageal cancer, pancreatic adenocarcinoma, breast cancer (metastatic), and other gastrointestinal cancers[2][4][6]. Capecitabine is often used as an alternative to intravenous 5-fluorouracil due to its oral administration route. The regimens may be referred to by acronyms such as CX (cisplatin + capecitabine) or CAPOX/XELOX (capecitabine + oxaliplatin)[2][6].

Brand names

AdrucilEloxatin

Other names

CDDP (cisplatin)5-FU (fluorouracil)XELODA (capecitabine)L-OHP (oxaliplatin)